Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Insider Sells 10,000 Shares of Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) insider James Hamilton sold 10,000 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $64.19, for a total transaction of $641,900.00. Following the completion of the sale, the insider owned 236,958 shares of the company’s stock, valued at approximately $15,210,334.02. The trade was a 4.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Arrowhead Pharmaceuticals Stock Up 1.4%

Shares of ARWR traded up $0.85 during trading hours on Monday, reaching $60.67. 2,260,641 shares of the stock traded hands, compared to its average volume of 3,102,574. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $76.76. The company has a market cap of $8.50 billion, a price-to-earnings ratio of 39.65 and a beta of 1.23. The stock has a fifty day simple moving average of $65.46 and a 200 day simple moving average of $50.29. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.29.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The firm had revenue of $264.03 million during the quarter, compared to the consensus estimate of $225.66 million. During the same period in the previous year, the company posted ($1.39) earnings per share. The company’s revenue for the quarter was up 10461.3% on a year-over-year basis. On average, equities analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Morgan Stanley lifted their price target on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 7th. Royal Bank Of Canada boosted their price target on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. Piper Sandler restated an “overweight” rating and set a $110.00 price target (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 13th. Weiss Ratings upgraded shares of Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, February 6th. Finally, The Goldman Sachs Group lifted their price objective on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 7th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, Arrowhead Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.67.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Corient Private Wealth LLC increased its holdings in Arrowhead Pharmaceuticals by 3.1% in the 4th quarter. Corient Private Wealth LLC now owns 18,226 shares of the biotechnology company’s stock worth $1,210,000 after acquiring an additional 551 shares during the last quarter. Bank of Hawaii bought a new position in Arrowhead Pharmaceuticals during the fourth quarter worth about $1,276,000. Invesco Ltd. increased its stake in shares of Arrowhead Pharmaceuticals by 8.9% in the fourth quarter. Invesco Ltd. now owns 547,758 shares of the biotechnology company’s stock worth $36,366,000 after purchasing an additional 44,866 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $352,000. Finally, Summit Global Investments lifted its stake in shares of Arrowhead Pharmaceuticals by 43.8% during the 4th quarter. Summit Global Investments now owns 14,287 shares of the biotechnology company’s stock valued at $949,000 after buying an additional 4,353 shares in the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.